| scholarly article | Q13442814 |
| P2093 | author name string | Stefano Calza | |
| Eleonora Marchina | |||
| Luigi Caimi | |||
| Alessandra Marengoni | |||
| Sophie Testa | |||
| Giuliana Martini | |||
| Oriana Paoletti | |||
| Giovanni Scovoli | |||
| Silvia Misasi | |||
| P2860 | cites work | Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions | Q26764853 |
| Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art | Q26776112 | ||
| Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis | Q27002899 | ||
| Crystal structure of human cytochrome P450 2C9 with bound warfarin | Q27641685 | ||
| Structural and functional insights into enzymes of the vitamin K cycle | Q28086880 | ||
| Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle | Q28238539 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy | Q28265249 | ||
| Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis | Q28296211 | ||
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk | Q33617751 | ||
| Genetic risk factors for major bleeding in patients treated with warfarin in a community setting | Q33792352 | ||
| Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q34252907 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials | Q34425072 | ||
| Warfarin pharmacogenetics | Q34785072 | ||
| Genotype and risk of major bleeding during warfarin treatment | Q35006973 | ||
| Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials | Q35550476 | ||
| Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial | Q36713982 | ||
| The largest prospective warfarin-treated cohort supports genetic forecasting | Q37071087 | ||
| Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis | Q37334140 | ||
| A pharmacogenetic versus a clinical algorithm for warfarin dosing | Q37616712 | ||
| Cytochrome P450 2C9-CYP2C9. | Q37691210 | ||
| Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. | Q37948826 | ||
| Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. | Q38194997 | ||
| Oral anticoagulation: a critique of recent advances and controversies | Q38362468 | ||
| Genotype-guided dosing of vitamin K antagonists | Q42844131 | ||
| VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement | Q43106358 | ||
| Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. | Q49142379 | ||
| The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. | Q50901189 | ||
| Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. | Q50950032 | ||
| A randomized trial of genotype-guided dosing of warfarin. | Q51140132 | ||
| Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events. | Q53092407 | ||
| Does Statin Therapy Decrease the Risk for Bleeding in Patients Who Are Receiving Warfarin? | Q57491218 | ||
| The impact of simvastatin on warfarin disposition and dose requirements | Q63241946 | ||
| VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection) | Q82891113 | ||
| Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population | Q87307841 | ||
| Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis | Q87368965 | ||
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e5451 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients | |
| P478 | volume | 95 |
| Q57794673 | Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin |
| Q89767315 | Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain |
| Q48665970 | The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. |
| Q53823783 | Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. |
Search more.